In this issue of JEM, Malissen and colleagues report that a gain-of-function mutation in CARMIL2, previously identified in patients, is sufficient to replace the contribution of CD28 to NF-κB activation and downstream effects in T cells, including in the setting of an anti-tumor response.

This review highlights how YTHDF proteins regulate tumor responses to radiotherapy by modulating DNA repair and the immune microenvironment and discusses their potential as therapeutic targets to enhance the efficacy of radiotherapy and immunotherapy in cancer treatment.

This review explores how aging alters the microvasculature and surrounding stromal cells, disrupting immune cell trafficking and promoting chronic inflammation. The authors highlight key molecular changes and propose therapeutic strategies targeting vascular aging to mitigate age-related inflammatory diseases.